A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19
Status:
Recruiting
Trial end date:
2022-11-10
Target enrollment:
Participant gender:
Summary
This phase I trial evaluates the side effects and best dose of COH04S1, a synthetic modified
vaccinia Ankara (MVA)-based SARS-CoV-2 vaccine, for the prevention of COVID-19. COVID-19 is
caused by the SARS-CoV-2 virus. SARS-CoV-2 has demonstrated the capability to spread rapidly,
leading to significant impacts on healthcare systems and causing societal disruption. COH04S1
was created by placing small pieces of SARS-CoV-2 DNA (the chemical form of genes) into
synthetic MVA, which may be able to induce immunity (the ability to recognize and fight
against an infection) to SARS-CoV-2. The purpose of this study is to determine the safety and
the optimal dose of the COH04S1 vaccine.